Zoetis Inc. (NYSE:ZTS) Shares Sold by Montag & Caldwell LLC

Montag & Caldwell LLC reduced its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 36.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 101,313 shares of the company's stock after selling 59,310 shares during the period. Zoetis comprises 3.5% of Montag & Caldwell LLC's investment portfolio, making the stock its 10th largest position. Montag & Caldwell LLC's holdings in Zoetis were worth $19,996,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of ZTS. Lake Street Financial LLC grew its position in shares of Zoetis by 11.6% in the 3rd quarter. Lake Street Financial LLC now owns 2,540 shares of the company's stock worth $442,000 after buying an additional 265 shares during the last quarter. AMI Asset Management Corp grew its position in shares of Zoetis by 1.1% in the 3rd quarter. AMI Asset Management Corp now owns 355,624 shares of the company's stock worth $61,871,000 after buying an additional 3,821 shares during the last quarter. Brookstone Capital Management grew its position in shares of Zoetis by 144.1% in the 3rd quarter. Brookstone Capital Management now owns 13,030 shares of the company's stock worth $2,190,000 after buying an additional 7,692 shares during the last quarter. Sumitomo Life Insurance Co. grew its position in shares of Zoetis by 2.9% in the 3rd quarter. Sumitomo Life Insurance Co. now owns 16,465 shares of the company's stock worth $2,865,000 after buying an additional 471 shares during the last quarter. Finally, PDS Planning Inc boosted its position in shares of Zoetis by 3.6% during the third quarter. PDS Planning Inc now owns 2,291 shares of the company's stock valued at $399,000 after purchasing an additional 80 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ZTS shares. Barclays dropped their price target on Zoetis from $260.00 to $230.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 23rd. Stifel Nicolaus dropped their price target on Zoetis from $215.00 to $195.00 and set a "buy" rating on the stock in a research report on Tuesday, April 2nd. The Goldman Sachs Group lifted their price target on Zoetis from $190.00 to $226.00 and gave the company a "buy" rating in a research report on Wednesday, January 17th. StockNews.com lowered Zoetis from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 20th. Finally, Piper Sandler restated an "overweight" rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $218.00.

Zoetis Stock Up 0.9 %

NYSE:ZTS traded up $1.36 during trading hours on Monday, reaching $159.78. 4,849,548 shares of the company traded hands, compared to its average volume of 3,141,330. The business's 50-day moving average price is $171.21 and its two-hundred day moving average price is $179.23. The stock has a market capitalization of $73.08 billion, a P/E ratio of 31.51, a P/E/G ratio of 2.42 and a beta of 0.85. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business had revenue of $2.21 billion during the quarter, compared to analysts' expectations of $2.19 billion. During the same quarter in the prior year, the firm earned $1.15 EPS. The firm's revenue for the quarter was up 8.5% compared to the same quarter last year. Analysts predict that Zoetis Inc. will post 5.79 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 1.08%. The ex-dividend date is Thursday, April 18th. Zoetis's dividend payout ratio is currently 34.12%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the business's stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the transaction, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 2,209 shares of company stock worth $371,293 over the last quarter. 0.16% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.